Chargement en cours...
DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats
Prolyl hydroxylase (PHD) inhibitors are being developed as alternatives to recombinant human erythropoietin (rHuEPO) for the treatment of anemia in patients with chronic kidney disease (CKD). However, the effects of PHD inhibitors and rHuEPO on blood pressure and CKD in animal models susceptible to...
Enregistré dans:
| Publié dans: | J Pharmacol Exp Ther |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The American Society for Pharmacology and Experimental Therapeutics
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6978707/ https://ncbi.nlm.nih.gov/pubmed/31801803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.262782 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|